Azhir, Cheng, et al use a validated electronic health record cohort and causal inference methods to assess the impact of Paxlovid on the risk of developing Long COVID. They find no overall reduction in risk, but observe fewer digestive symptoms and modest benefit in older, non-hospitalized adults.
- Alaleh Azhir
- Jingya Cheng
- Hossein Estiri
